                                                                    EXHIBIT 99.1
                                                                    ------------

CONTACTS
Robin Smith, CEO                              Stanley Wunderlich/Daniel Stepanek
NeoStem, Inc.                                 Consulting for Strategic Growth 1
420 Lexington Ave., Ste. 450                  800 Second Avenue
NY, NY 10170                                  New York, NY 10017
Tel: (212) 584-4180                           Tel: (800) 625-2236
Fax: (646) 514-7787                           Fax: (212) 337-8089
Email: rsmith@neostem.com                     Emails: info@cfsg1.com
Web site: www.neostem.com                             dstepanek@cfsg1.com
                                              Web site: www.cfsg1.com

                                                           FOR IMMEDIATE RELEASE

  NEOSTEM COMPLETES $2.5 MILLION FINANCING TO ADVANCE THE COMPANY'S GROWTH PLAN

     NEW YORK, NY, Feb 7, 2007 - NeoStem, Inc. (OTCBB:NEOI), the only company
specializing in the collection, processing and long-term storage of Adult Stem
Cells (ASCs) for autologous use, announced today that it has completed a $2.5
million private placement of common stock and warrants. Proceeds from the
offering will be used to accelerate the Company's growth plan, including
expansion of Adult Stem Cell Collection Centers and the NeoStem Physicians
Network.

     Emerging Growth Equities, Ltd. acted as the placement agent for this
transaction.

     NeoStem's CEO, Robin L. Smith, MD, MBA, stated, "We are extremely pleased
to announce the closing of this financing. This infusion of capital will allow
us to pursue opportunities that should drive our growth over the next several
years. We are very excited to have the support of investors, such as well known
venture capitalists John Pappajohn and Cliff Henry, who understand the potential
for adult stem cell therapeutics that are emerging with the advances of
regenerative medicine for heart disease, skeletal repair, skin wounds, burns,
radiation exposure and autoimmune disorders such as lupus, multiple sclerosis
and rheumatoid arthritis. By storing his or her own stem cells, a patient can
create bio-insurance against future need while eliminating potential issues of
tissue matching and rejection. NeoStem is the first commercial company to
provide safe and convenient autologous stem cell processing and long-term
storage for stem cells derived from adults."

     During the remainder of 2007, NeoStem is moving to:

     o    Expand its network of participating physicians;
     o    Establish Adult Stem Cell Collection Centers throughout the
          continental United States;
     o    Establish strategic relationships with leading pharmaceutical and
          biotechnology companies;
     o    Partner with major academic institutions to enhance translational
          research;
     o    Market its services to those educated in the value of stem cells;
     o    Enhance the Company's distinguished Board of Directors and Scientific
          and Advisory Boards; and
     o    Expand its patent portfolio in the identification, collection,
          mobilization and storage of autologous stem cells.

ABOUT NEOSTEM, INC.

     NeoStem, Inc. (OTCBB:NEOI) is in the business of processing and long-term
storage of stem cells safely extracted from adults for multiple uses by the
individual in the future. NeoStem and its network of providers use a safe,
minimally invasive procedure -- apheresis -- to collect the cells. Using its
proprietary process, NeoStem provides the infrastructure, methods and systems
that allow adults to have their stem cells safely collected and conveniently
banked for multiple future therapeutic uses, as needed, in the treatment of such
diseases as diabetes, heart disease, cancer and radiation sickness. Further
potential uses for adult stem cells include regenerative therapies for wound
healing, autoimmune diseases such as multiple sclerosis and lupus, and
age-related degenerative musculoskeletal diseases. NeoStem's first processing
and storage bank facility has been licensed by the State of California and is
operating in Los Angeles.

     Certain statements in this press release constitute "forward-looking
statements" within the meaning of the Private Securities Litigation Reform Act
of 1995, including statements concerning the ability of NeoStem, Inc. ("the
Company") to develop the adult stem cell business, the future of regenerative
medicine and the role of adult stem cells in that future, the future use of
adult stem cells as a treatment option and the potential revenue growth of the
Company's business. Such forward-looking statements involve known and unknown
risks, uncertainties and other factors, which may cause the actual results,
performance or achievements of the Company, or industry results, to be
materially different from any future results, performance, or achievements
expressed or implied by such forward-looking statements. The Company' s ability
to enter the adult stem cell arena and future operating results are dependent
upon many factors, including but not limited to (i) the Company's ability to
obtain sufficient capital or a strategic business arrangement to fund its
expansion plans; (ii) the Company's ability to build the management and human
resources and infrastructure necessary to support the growth of its business and
obtain appropriate state licenses; (iii) competitive factors and developments
beyond the Company's control; (iv) scientific and medical developments beyond
the Company's control, including developments in the potential therapeutic use
of adult stem and (v) other risk factors discussed in the Company's periodic
filings with the Securities and Exchange Commission which are available for
review at www.sec.gov under "Search for Company Filings."
